COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01305356
Recruitment Status : Completed
First Posted : February 28, 2011
Results First Posted : December 5, 2018
Last Update Posted : December 26, 2018
Information provided by (Responsible Party):
BioMimetic Therapeutics

Brief Summary:


To demonstrate equivalent clinical and radiologic outcomes as "gold standard" (Autologous Bone Graft) in a representative clinical model (hindfoot fusions)


Augment® Injectable is an equivalent bone grafting substitute to autologous bone graft in applications as shown by superiority analysis for safety and non-inferiority analysis for effectiveness


To evaluate a fully synthetic bone graft material to facilitate fusion in conditions or injuries requiring bone graft in a representative clinical fusion model and thus the opportunity to provide equivalent union rates as Autologous Bone Graft without necessitating an additional invasive procedure to harvest the graft

Condition or disease Intervention/treatment Phase
Degenerative Joint Disease Congenital Deformity Arthritis Osteoarthritis Rheumatoid Arthritis Device: Augment® Injectable Bone Graft Procedure: Autologous bone graft Not Applicable

Detailed Description:


Prospective, randomized, controlled, non-inferiority, multi-center trial




299 Subjects (see "Study Population"). The subject population included subjects enrolled in 3 separate Clinical Trials. (BMTI-2006-01, BMTI-2009-01, and BMTI-2010-01)


Male and female subjects 18 years of age or older requiring a hindfoot fusion procedure involving a bone grafting procedure.


Group I: Standard Rigid Fixation + Autologous Bone Graft Group II: Standard Rigid Fixation + Augment® Injectable Bone Graft

Subjects will be randomized in a 2:1 ratio (Augment® Injectable:Autologous Bone Graft).


Investigational device is manually implanted inside and around the fusion space to ensure Augment® Injectable Bone Graft (beta-TCP/bovine collagen matrix +rhPDGF-BB) or autologous bone graft is contained within the joint space


Twenty-four month follow-up post-surgery

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 299 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Controlled, Multi-Center, Pivotal Human Clinical Trial to Evaluate the Safety and Effectiveness of Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Actual Study Start Date : March 2011
Actual Primary Completion Date : April 2013
Actual Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bone Grafts

Arm Intervention/treatment
Experimental: Augment® Injectable Bone Graft
Standard rigid fixation + Augment® Injectable Bone Graft (beta-TCP/bovine collagen matrix + rhPDGF-BB)
Device: Augment® Injectable Bone Graft
Implantation of up to 9cc of Augment® Injectable Bone Graft

Active Comparator: Autologous bone graft
Standard Rigid Fixation + Autologous bone graft
Procedure: Autologous bone graft
Implantation of up to 9cc of autologous bone graft

Primary Outcome Measures :
  1. Pain on Weight Bearing [ Time Frame: Baseline, 9, 12, 16, 24, 36, and 52 weeks ]
    Subjects were asked to stand and report pain on a 100 mm Visual Analog Scale (with 0 being no pain and 100 being worst pain imaginable).

Secondary Outcome Measures :
  1. Foot Function Index (FFI) [ Time Frame: Baseline, 9, 12, 16, 24, 36, and 52 weeks ]
    The Foot Function Index (FFI) measures the impact of foot pathology on function in terms of pain, disability and activity restriction. The FFI is a self-administered index consisting of 23 items divided into 3 sub-scales all ranging from 0-100. To obtain a sub-scale score, the item scores for a sub-scale are totaled and then divided by the maximum total possible for all of the sub-scale items which the subject indicated were applicable. Any item marked as not applicable is excluded from the total possible. Sub-scales are an average of the completed ratings within that sub-scale. The total foot function score is an average of the three sub-scale scores and ranges from 0-100. Lower scores are indicative of better outcomes whereas higher scores indicate greater impairment.

  2. AOFAS Hindfoot and Ankle Score [ Time Frame: Baseline, 9, 12, 16, 24, 36, and 52 weeks ]
    Subjects were asked to report pain, functionality and ability levels while the physician performed assessments based on alignment, abnormality, motion, and stability. The total score ranges from a low of zero to a high of 100, with subscales measuring pain (40 points), function (50 points), and alignment (10 points), with higher scores showing better outcomes.

  3. Fusion Site Pain [ Time Frame: Baseline, 9, 12, 16, 24, 36, and 52 weeks ]
    Subjects were asked to report current pain level at the fusion site on a 100 mm Visual Analog Scale (with 0 being no pain and 100 being worst pain imaginable).

  4. SF-12 Physical Component Score [ Time Frame: Baseline, 9, 12, 16, 24, 36, and 52 weeks ]
    The SF-12 Physical Component Score is a validated quality of life metric with a minimum of zero and a maximum of 100, with higher scores denoting higher quality of life.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • at least 18 years old and considered skeletally mature
  • diagnosed with degenerative joint disease (DJD) affecting the hindfoot due to a congenital or acquired deformity, osteoarthritis, rheumatoid arthritis, post- traumatic arthritis or ankylosing spondylitis of the ankle, subtalar, calcaneocuboid, and/or talonavicular joints
  • requires one of the following hindfoot fusion proceduress with supplemental bone graft/substitute: ankle fusion (tibiotalar), subtalar fusion (talocalcaneal), calcaneocuboid fusion, talonavicular fusion, triple arthrodesis (subtalar, talonavicular and calcaneocuboid joints) OR double fusions (any combination of any two of the following: subtalar, talonavicular and calcaneocuboid joints)
  • fusion site able to be rigidly stabilized with no more than 3 screws across the fusion site

    • supplemental pins or staples allowed
    • supplemental screws external to the fusion site(s) allowed
  • signed informed consent document, independent, ambulatory, and can comply with all post-operative evaluations and visits


  • undergone previous fusion surgery at the proposed location, i.e., revision of a failed fusion
  • more than one previous procedure at the involved joints
  • retained hardware spanning the joint(s) intended for fusion
  • procedure anticipated to require plate fixation (including claw plates), IM nails or more than 3 screws to achieve rigid fixation based on pre-op planning
  • procedure expected to require more than 9cc of graft material based on pre-op planning
  • procedure expected to require structural bone graft, allograft, bone graft substitute, platelet rich plasma (PRP) or bone marrow aspirate
  • procedure expected to require a pantalar fusion, i.e., fusion of ankle plus all hindfoot joints (talonavicular, subtalar, and calcaneocuboid) or an ankle fusion in combination with any hindfoot fusion
  • radiographic evidence of bone cysts, segmental defects or growth plate fracture near the fusion site that could negatively impact the proposed fusion procedure
  • tested positive or been treated for a malignancy in the past or is suspected of having a malignancy or currently undergoing radio- or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed surgical site
  • pre-existing sensory impairment, e.g., diabetics with baseline sensory impairment, which limits ability to perform objective functional measurements and may be at risk for complications

    - diabetics not sensitive to the 5.07 monofilament (Semmes-Weinstein) are to be excluded

  • metabolic disorder known to adversely affect the skeleton other than primary osteoporosis or diabetes, e.g., renal osteodystrophy or hypercalcemia
  • use of chronic medications known to affect the skeleton, e.g., glucocorticoid usage > 10mg/day
  • pre-fracture neuromuscular or musculoskeletal deficiency which limits the ability to perform objective functional measurements
  • physically or mentally compromised, e.g., current treatment for a psychiatric disorder, senile dementia, Alzheimer's disease, etc., to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant
  • allergic to yeast-derived products or bovine collagen or other bovine-sourced products
  • received an investigational therapy within 30 days of proposed surgery or during the follow-up phase of the study
  • is a prisoner, known or suspected transient or a history of drug/alcohol abuse within the 12 months prior to screening
  • pregnant or intending to become pregnant within 12 months of the study procedure
  • morbidly obese defined as BMI > 45 kg/m2
  • currently has an acute infection at the surgical site

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01305356

Show Show 25 study locations
Sponsors and Collaborators
BioMimetic Therapeutics
Layout table for investigator information
Study Director: Stephen Roach Wright Medical Technology
Principal Investigator: Christopher DiGiovanni, MD University Orthopaedics, Inc.
Publications of Results:
Layout table for additonal information
Responsible Party: BioMimetic Therapeutics Identifier: NCT01305356    
Obsolete Identifiers: NCT01008891
Other Study ID Numbers: BMTI-2010-01
First Posted: February 28, 2011    Key Record Dates
Results First Posted: December 5, 2018
Last Update Posted: December 26, 2018
Last Verified: December 2018
Keywords provided by BioMimetic Therapeutics:
degenerative joint disease
joint fusion
congenital deformity
rheumatoid arthritis
post-traumatic arthritis
ankylosing spondylitis
Augment(tm) Injectable Bone Graft
autologous bone graft
autogenous bone graft
bovine collagen
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Congenital Abnormalities
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases